Pluvicto improves survival in metastatic hormone-sensitive prostate cancer across patient subgroups, Novartis reports

Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), regardless of disease volume or presentation. The Phase 3 PSMAddition trial showed a 28% reduction in risk of progression or death, supporting early use of Pluvicto in this patient group. Safety profiles were consistent, with manageable side effects. Novartis also presented promising Phase 1 data for its actinium-based radioligand therapy, 225 Ac-PSMA-617, advancing two Phase 3 trials for metastatic castration-resistant prostate cancer (mCRPC). Regulatory decisions for Pluvicto are expected in the second half of 2026.